Improvement in clinical outcome ofFLT3ITD mutated acute myeloid leukemia patients over the last one and a half decade
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improvement in clinical outcome ofFLT3ITD mutated acute myeloid leukemia patients over the last one and a half decade
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 11, Pages 1065-1070
Publisher
Wiley
Online
2015-08-24
DOI
10.1002/ajh.24140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations
- (2014) Yesid Alvarado et al. CANCER
- The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial
- (2014) M Lazenby et al. LEUKEMIA
- AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
- (2014) C. Li et al. MOLECULAR CANCER THERAPEUTICS
- Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
- (2013) M. Pratcorona et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
- (2012) Salut Brunet et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
- (2011) Friederike Schneider et al. ANNALS OF HEMATOLOGY
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
- (2011) Amy E. DeZern et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype
- (2011) K. Wagner et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
- (2009) Farhad Ravandi et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search